Dec 12 (Reuters) - Trevi Therapeutics TRVI.O:
TREVI THERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM SAMPLE SIZE RE-ESTIMATION RESULTING IN NO CHANGE TO THE CURRENT SAMPLE SIZE FOR THE PHASE 2B CORAL TRIAL IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS WITH CHRONIC COUGH
TREVI THERAPEUTICS INC - TRIAL REACHES 75% ENROLLMENT, TOPLINE RESULTS EXPECTED IN H1 2025
TREVI THERAPEUTICS INC - SSRE RECOMMENDS CONTINUATION OF CORAL TRIAL AS PLANNED
Source text: ID:nPn3LSkxka
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.